Genentech Biooncology
Genentech Biooncology
    • Home 

    • Research Education 

    • Research HER Pathways 

    • Overview 

    • GLOSSARY
    • ON
    • OFF
  • Print
  • share
 
 
' The related resources bookmark allows you to jump directly to other pages on the site that contain information directly related to the topics you're currently exploring.
  • Home Page
  • What's New?
  • Tumor Types
  • Molecular Causes of Cancer
  • Biological Pathways
  • Therapeutic Targets
  • Pipeline Molecules
  • Research Education
    • Research ADCs
    • Research Apoptosis
    • Research B cell
    • Research BRAF
    • Research Cancer Immunotherapy
    • Research HDIs
    • Research HER Pathways
      • Overview
        • HER receptors
        • HER ligands
        • Receptor activation
        • Dimerization
        • Cancer effects
        • Therapeutic potential of HER pathways
        • Summary
        • References
      • HER1/EGFR
      • HER2:HER3 dimer
      • HER2
      • HER3
      • HER4
      • HER pathways slide decks and videos
      • Glossary
    • Research MET
    • Research VEGF
  • Clinical Trials
  • Resources
  • Contact Us
Register for Updates Unsubscribe Share
Register for Updates Unsubscribe Share

Related Resources for this page:

  • Tumor Types
    • Breast Cancer
    • Ovarian Cancer
  • Molecular Causes of Cancer
    • Evading growth suppressors
  • Biological Pathways
    • HER Signaling
  • Therapeutic Targets
    • HER1
    • HER2
    • HER3
    • HER4
  • Clinical Trials
    • Breast Cancer
    • Ovarian Cancer
  • Cancer Biomarkers
    • Breast Cancer
      • Receptor-Mediated Endocytosis
      • Genome instability and mutation
      • Cytotoxic agent
      • What are ADCs?
      • Stable linker
      • Monoclonal antibody
      • Current research in ADCs
      • Targeting cancers with ADCs
      • Glossary
      • A brief history of ADCs
      • How are ADCs designed to work?
      • Research ADCs
      • Multimedia Resources
      • HER2+ breast cancer
      • HER2 dimerization
      • Research HDIs
      • Slide decks and videos
      • Breast Cancer
    • Ovarian Cancer
      • Receptor-Mediated Endocytosis
      • Cytotoxic agent
      • What are ADCs?
      • Stable linker
      • Monoclonal antibody
      • Current research in ADCs
      • Targeting cancers with ADCs
      • Glossary
      • A brief history of ADCs
      • How are ADCs designed to work?
      • Research ADCs
      • Multimedia Resources
      • Oncogenic BRAF in cancer
      • VEGF in ovarian cancer
      • VEGF as a prognostic factor in ovarian cancer
      • Summary
  • Future Directions
    • Antibody-Drug conjugates
      • HER Signaling
      • Receptor-Mediated Endocytosis
      • Cytotoxic agent
      • What are ADCs?
      • Stable linker
      • Monoclonal antibody
      • Current research in ADCs
      • Targeting cancers with ADCs
      • Glossary
      • A brief history of ADCs
      • How are ADCs designed to work?
      • Research ADCs
      • Multimedia Resources
      • Summary
    • Glycoengineered Antibodies
      • HER Signaling
      • Summary
    • Non-Antibody Biologics
      • Apoptosis
      • Summary
    • Targeted Small Molecules
      • Apoptosis
      • MAPK Signaling
      • PI3K/Akt/mTOR Signaling
      • MEK Inhibitor (GDC-0973)
      • PI3K Inhibitor (GDC-0941)
      • Glossary
      • Resisting apoptosis
      • Slide decks and videos
      • Summary
      • Gastric Cancer
    • Traditional Monoclonal Antibodies
      • Angiogenic Signaling
      • HER Signaling
      • Inhibition of HER2 dimerization
      • Glossary
      • Slide decks and videos
      • Summary
      • Gastric Cancer
Overview Slide Deck

Slide Deck

View the HER Pathways Overview slide deck

View Slide Deck
Share

HER Pathways are of critical importance in cancer

Beginning with benign hyperplasia and extending through invasive metastasis, a number of studies demonstrate that [HER family] receptor activation can play a major role in all aspects of cancer development.

— Sliwkowski MX, "Alterations in the ErbB Signaling Network in Breast Cancer"1

This section of ResearchHERPathways.com introduces the HER receptors and the methods in which they interact. Click on the links below to learn more.

  • What are HER receptors?
  • What are ligands and how do they relate to receptors?
  • How are HER receptors activated?
  • What is receptor dimerization? What are downstream signaling effects?
  • What tumor types are influenced by HER pathways?
  • Can HER pathways be therapeutic targets?
  • Summary of HER pathways in cancer

View References for this site section

 
  • SITEMAP
  • /
  • PRIVACY POLICY
  • /
  • TERMS & CONDITIONS
  • /
  • CONTACT US
  • /
  • © 2013 Genentech USA, Inc. All rights reserved.
  • /
  • BIO0000907901
Next section: HER receptors »

© 2011 Genentech USA, Inc. All rights reserved